Skip Navigation Links
Centers for Disease Control and Prevention
CDC Home Search Health Topics A-Z

DISSS Home | Contact Us
 Health and Human Services Logo

Animated FirstGov Logo - Click to enter FirstGov

Tuberculosis (Mycobacterium tuberculosis)

Home - National Notifiable Diseases Surveillance System
List of Nationally Notifiable Diseases
Alphabetical List of Case Definitions
Definition of Terms
Related Links
  Site Search

1996 Case Definition

Clinical description

A chronic bacterial infection caused by Mycobacterium tuberculosis, characterized pathologically by the formation of granulomas. The most common site of infection is the lung, but other organs may be involved.

Clinical case definition

A case that meets the following criteria:

  • A positive tuberculin skin test
  • Other signs and symptoms compatible with tuberculosis (e.g., an abnormal, unstable [i.e., worsening or improving] chest radiographs, or clinical evidence of current disease)
  • Treatment with two or more antituberculosis medications
  • Completed diagnostic evaluation

Laboratory criteria for diagnosis

  • Isolation of M. tuberculosis from a clinical specimen* or
  • Demonstration of M. tuberculosis from a clinical specimen by nucleic acid amplification test,** or
  • Demonstration of acid-fast bacilli in a clinical specimen when a culture has not been or cannot be obtained

Case classification

Confirmed: a case that meets the clinical case definition or is laboratory confirmed


A case should not be counted twice within any consecutive 12-month period. However, cases in which the patients had previously had verified disease should be reported again if the patients were discharged from treatment. Cases also should be reported again if patients were lost to supervision for greater than 12 months and disease can be verified again. Mycobacterial diseases other than those caused by M. tuberculosis complex should not be counted in tuberculosis morbidity statistics unless there is concurrent tuberculosis.

*Use of rapid identification techniques for M. tuberculosis (e.g., DNA probes and mycolic acids high-pressure liquid chromatography performed on a culture from a clinical specimen) are acceptable under this criterion. **Nucleic acid amplification (NAA) tests must be accompanied by culture for mycobacteria species. However, for surveillance purposes, CDC will accept results obtained from NAA tests approved by the Food and Drug Administration (FDA) and used according to the approved product labeling on the package insert. Current FDA-approved NAA tests are only approved for smear-positive respiratory specimens.

See also:

Printable Version



Privacy Policy | Accessibility

DISSS Home | Contact Us

CDC Home | Search | Health Topics A-Z

This page last updated January 9, 2008

United States Department of Health and Human Services
Centers for Disease Control and Prevention

"Epi Info" is a trademark of the Centers for Disease Control and Prevention (CDC).